secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0000950170-23-069210
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics raises $25M via pre-funded warrant private placement for SMARCA2 pipeline
--------------------------------------------------------------------------------

- Gross proceeds ~$25M from sale of 7,936,759 pre-funded warrants at $3.1499 each, exercise price $0.0001.
- Net proceeds estimated at $24.9M after offering expenses.
- Funds primarily support SMARCA2 portfolio: IV molecule PRT3789 clinical development and oral program IND.
- Cash runway now expected into 2026; closing expected Dec 13, 2023.
- Warrants are immediately exercisable, subject to 4.99% beneficial ownership cap (waivable to 19.99%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/prld-20231211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-069210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer